Aug 25, 2026 07:00AM
Aug 4, 2026 04:01PM
Jun 15, 2026 06:41AM
Jun 15, 2026 06:40AM
Jun 11, 2026 08:00AM
May 30, 2026 02:30PM
May 27, 2026 07:02AM Precigen gets seven-year US exclusivity for rare disease drug PAPZIMEOS
May 27, 2026 07:00AM
May 13, 2026 04:05PM
Apr 7, 2026 07:01AM
Apr 7, 2026 07:00AM
Mar 25, 2026 04:05PM
Jan 20, 2026 08:06AM
Jan 20, 2026 08:05AM New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis
Jan 12, 2026 08:04AM
Jan 12, 2026 08:00AM
Nov 13, 2025 04:05PM
Oct 13, 2025 07:01AM
Oct 13, 2025 07:00AM
Aug 25, 2025 08:05AM
Aug 19, 2025 06:38AM H.C. Wainwright Reiterates Buy Rating on Precigen Inc. (PGEN)
Aug 15, 2025 07:00AM
Aug 15, 2025 07:00AM
May 15, 2025 07:22AM
May 14, 2025 04:05PM
Apr 16, 2025 08:05AM
Mar 20, 2025 06:41AM
Mar 19, 2025 04:05PM Precigen Reports Full Year 2024 Financial Results and Business Updates
Feb 25, 2025 09:10AM
Feb 25, 2025 08:05AM
Feb 25, 2025 08:05AM
Jan 13, 2025 07:00AM
Jan 2, 2025 04:00PM
Dec 30, 2024 07:00AM
Nov 14, 2024 04:30PM Precigen Reports Third Quarter 2024 Financial Results and Business Updates
Aug 14, 2024 04:05PM
Aug 6, 2024 04:08PM
Aug 6, 2024 04:01PM
Jul 23, 2024 08:01AM
Jul 23, 2024 08:01AM
Jun 3, 2024 09:30AM
Jun 3, 2024 09:30AM Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response
May 23, 2024 05:00PM
May 14, 2024 04:05PM
Apr 24, 2024 10:20AM
Mar 28, 2024 04:05PM
Mar 20, 2024 03:16PM
Mar 19, 2024 04:05PM
Mar 12, 2024 04:05PM Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
Jan 16, 2024 08:05AM

330,011 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All